Skip to Content
How to talk to a doctor about advanced ovarian cancer >>

Ofatumumab Pregnancy and Breastfeeding Warnings

Ofatumumab is also known as: Arzerra

Ofatumumab Pregnancy Warnings

Animal studies have not demonstrated maternal toxicity or teratogenicity in the fetus, but did reveal evidence of depletion of peripheral B cells and decreased spleen and placental weights. There are no controlled data in human pregnancy. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

Benefit should outweigh risk. AU TGA pregnancy category: C US FDA pregnancy category: Not assigned Comments: -The manufacturer recommends that breastfeeding should be discontinued for the duration of treatment and for 12 months following treatment discontinuation. -This drug may cause fetal B-cell depletion based on findings from animal studies and the mechanism of action of the drug. Live vaccines should not be administered to neonates and infants exposed to this drug in utero until B-cell recovery occurs.

See references

Ofatumumab Breastfeeding Warnings

Safety has not been established Excreted into human milk: Unknown Excreted into animal milk: Unknown Comments: -The effects in the nursing infant are unknown. -The manufacturer recommends that breastfeeding should be discontinued for the duration of treatment and for 12 months following treatment discontinuation.

-No information is available on the use of this drug during breastfeeding. Because it is a large protein molecule, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant GI tract. -Human IgG is secreted in human milk. Published data suggest that neonatal and infant consumption of breast milk does not result in substantial absorption of these maternal antibodies into circulation.

See references

References for pregnancy information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):
  3. "Product Information. Arzerra (ofatumumab)." GlaxoSmithKline, Research Triangle Park, NC.

References for breastfeeding information

  1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
  2. "Product Information. Arzerra (ofatumumab)." GlaxoSmithKline, Research Triangle Park, NC.
  3. Pharmaceutical Society of Australia "APPGuide online. Australian prescription products guide online. Available from: URL: http://www.appco.com.au/appguide/default.asp." ([2006]):
  4. United States National Library of Medicine "Toxnet. Toxicology Data Network. Available from: URL: http://toxnet.nlm.nih.gov/cgi-bin/sis/htmlgen?LACT." ([cited 2013 -]):

See Also...

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and Drugs.com is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide